They observed that cocaine and meth significantly altered glycan and sulfate contents and compositions for heparan sulfate ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could ...

Figure 1: Heparan sulfate proteoglycan is a receptor for AAV-2 virions. Identification of the AAV receptor and vector-specific reagents has led to the development of purification protocols for ...

Joseph Arboleda-Velasquez of Harvard Medical School praised the results. “Ye’s group has now provided compelling evidence showing increased binding affinity of ApoE3 Christchurch for tau and its ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

These ligands circulate throughout the body owing to weak affinity for HSGAG (heparan sulphate glycosaminoglycan), and they require α-klotho–β-klotho proteins as cofactors for their activity.

Chondroitin Sulfate, Heparan Sulfate and proteoglycans (PG) (decorin, versican and aggrecan) respectively were performed on normal and pathological tendon sections from rat supraspinatus and human ...